Shares of Savara Pharmaceuticals (NASDAQ: SVRA) fell nearly 76% on Thursday after the company reported that molgradex failed to meet the primary endpoint in a phase 3 study.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,